{"response_id": "kimi-k2.5:cloud|GEN-SM-02", "question_id": "GEN-SM-02", "pair_id": "GEN-02", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Why do graph-based molecular generators often yield higher validity rates than naive character-level SMILES generators?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Graph-based molecular generators achieve higher validity rates (typically **>90–95%** vs. **60–80%** for naive character-level SMILES models) because they encode chemical constraints directly into the generation process, whereas SMILES generators must learn complex, error-prone linear syntax rules.\n\n**Key reasons:**\n\n1. **Explicit valence and bonding constraints**  \n   Graph generators construct molecules by predicting node (atom) types and edge (bond) adjacency matrices. They can enforce hard chemical rules during generation—e.g., carbon cannot exceed four bonds, or nitrogen cannot form five single bonds—ensuring atom-wise validity at each step. In contrast, character-level SMILES models generate linear strings (e.g., `C1=CC=CC=C1`) and frequently violate valence rules or produce chemically impossible connectivity (e.g., pentavalent carbon) because they lack explicit chemical constraints in the decoding logic.\n\n2. **Ring closure and branching syntax**  \n   SMILES requires matched pairs of ring-closure digits (e.g., `C1...C1`) and balanced parentheses for branches. Character-level LSTMs/Transformers often fail to capture these long-range dependencies, generating unmatched indices (e.g., `C1CCCCC`) or invalid nesting. Graph generators explicitly define cycles through edges in the adjacency matrix, eliminating the \"syntax error\" class of invalidity entirely.\n\n3. **Robustness to minor perturbations**  \n   In SMILES, a single character change (e.g., altering `C` to `N` or", "latency_ms": 18656, "timestamp": "2026-02-09T07:37:29.485245+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 28399, "timestamp": "2026-02-09T07:40:12.378754+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 18326, "timestamp": "2026-02-09T07:47:20.204212+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-06", "question_id": "ASSAY-PEP-06", "pair_id": "ASSAY-06", "category": "Assay Interpretation", "domain": "peptide", "question_text": "An antimicrobial peptide has MIC = 5 µg/mL and hemolysis HC50 = 25 µg/mL. Compute TI (HC50/MIC) and state why this is a concern and one design direction to reduce hemolysis.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **TI = 5** (25 µg/mL ÷ 5 µg/mL).\n\n**Concern:** This indicates a narrow therapeutic window. The concentration required for antimicrobial efficacy is only 5-fold lower than that causing 50% red blood cell lysis, creating a high risk of hemolytic toxicity at therapeutic doses. Selectivity is poor; desirable AMPs typically have TI > 10–100 (preferably >100).\n\n**Design direction:** **Reduce hydroph", "latency_ms": 14696, "timestamp": "2026-02-09T07:48:08.654085+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-05", "question_id": "SAR-PEP-05", "pair_id": "SAR-05", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s backbone NH at a specific position donates a critical hydrogen bond to the target (distance ~2.9 Å). What is the expected effect on activity of N-methylating that backbone amide at the same position, and what secondary benefit might occur?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Expected effect on activity:** Significant reduction or complete loss of binding affinity (and thus activity). N-methylation replaces the backbone N–H with N–CH₃, abolishing the hydrogen bond donor. Since the N–H donates a critical H-bond (2.9 Å is optimal geometry, contributing roughly **1–3 kcal/mol** to binding), removing it typically increases the dissociation constant (K<sub>d</sub>) by **10- to 100-fold** or greater, depending on whether the interaction is solvent-exposed or buried.\n\n**Secondary benefit:** Enhanced **proteolytic stability** and potential improvement in **membrane permeability**. N-methylation masks the amide bond from recognition by peptidases, slowing enzymatic degradation. It also reduces the number of hydrogen bond donors (HBDs), which can improve passive diffusion across lipid membranes and align better with Lipinski/Veber rules for oral bioavailability.", "latency_ms": 36164, "timestamp": "2026-02-09T07:50:51.290880+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-03", "question_id": "OPT-PEP-03", "pair_id": "OPT-03", "category": "Optimization Approaches", "domain": "peptide", "question_text": "In phage display affinity maturation, name two experimental knobs that increase selection stringency across rounds and explain the expected effect on the enriched pool.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two experimental knobs to increase selection stringency in phage display affinity maturation are:\n\n**1. Decreasing antigen concentration**  \nReducing the coating concentration of target antigen from typical starting levels (e.g., 10–100 nM or 1–10 µg/mL) to sub-nanomolar concentrations (e.g., 0.1–1 nM) in later rounds. At lower antigen densities, only phage displaying binders with high affinity (low nanomolar to picomolar *K*<sub>d</sub>) can effectively compete for limited binding sites, while low-affinity clones (micromolar *K*<sub>d</sub>) are lost due to mass-action effects.\n\n**2. Increasing wash stringency**  \nEscalating the number, duration, or harshness of washing steps (e.g., progressing from 3 brief washes to 5–10 extended washes with high-salt buffers [0.5–1 M NaCl], detergents [0.1–0.5% Tween-20], or chaotropic agents). This applies selective pressure for slow off-rates (*k*<sub>off</sub>), dissociating unstable phage-antigen complexes and enriching for clones with higher binding stability.\n\n**Expected effect on the enriched pool:**  \nThe pool shifts from polyclonal, moderate-", "latency_ms": 18184, "timestamp": "2026-02-09T07:52:17.877801+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-06", "question_id": "GEN-SM-06", "pair_id": "GEN-06", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Name two generation-time techniques that increase diversity of generated small molecules and one quantitative metric commonly used to measure diversity in molecular sets.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two generation-time techniques that increase molecular diversity are:\n\n1. **Temperature sampling** – increasing the softmax temperature parameter (T > 1.0, typically 1.2–1.5) during decoding from generative models (e.g., SMILES-based RNNs or transformers) to flatten the probability distribution and sample less likely tokens.\n2. **Diverse beam search** – modifying standard beam search with diversity penalties (e.g., hamming diversity or rank-based penalties) that discourage similar sequences from occupying multiple beam slots, forcing exploration of disparate chemical spaces.\n\nOne quantitative metric commonly used is **Internal", "latency_ms": 14720, "timestamp": "2026-02-09T07:52:35.598600+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-01", "question_id": "SAR-PEP-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide ligand has a Leu side chain that inserts into a hydrophobic subpocket adjacent to an aromatic residue that can support edge-to-face π interactions. If the Leu-containing peptide has Kd = 200 nM, what is the most likely binding change when substituting that Leu with Phe, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 22933, "timestamp": "2026-02-09T07:55:08.661030+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-06", "question_id": "OPT-SM-06", "pair_id": "OPT-06", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A small molecule inhibits both the intended kinase and a close off-target kinase. Structural data indicate the intended target has a larger lipophilic pocket extension that the off-target lacks. What modification strategy is most likely to improve selectivity, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Strategy:** Add a lipophilic substituent (e.g., alkyl, aryl, or cycloalkyl group) that projects into the extended lipophilic pocket present in the intended target but absent in the off-target.\n\n**Why:** This exploits the structural difference through steric and hydrophobic complementarity. The added group forms favorable van der Waals interactions within the larger pocket of the intended target, maintaining or improving potency. In the off-target, which lacks this cavity, the same substituent causes steric clash or unfavorable desolvation without compensating interactions, reducing binding affinity. \n\n**Typical implementation:** Extension from a solvent-exposed region of the inhibitor scaffold with groups like isopropyl, cyclopropyl, phenyl, or gem-dimethyl groups—often increasing lipophicity (clogP) by 0.5–2.0 units while improving selectivity ratios 10–100-fold. This approach is exemplified by selective CDK4/6 inhibitors (e.g., palbociclib) or BTK inhibitors that exploit unique hydrophobic pockets adjacent to the ATP-binding site.", "latency_ms": 30251, "timestamp": "2026-02-09T07:55:41.912889+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-08", "question_id": "SAR-PEP-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds as an α-helix but is mostly disordered in solution. Stapling increases preorganization and improves binding free energy by ~1.0 kcal/mol. Approximately what fold-improvement in affinity would you expect at 298 K, and what is the mechanism?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 14324, "timestamp": "2026-02-09T07:58:12.636178+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-10", "question_id": "OPT-SM-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "You have four compounds with (IC50 nM, solubility µM, clearance mL/min/kg): A(10, 5, 40), B(30, 50, 20), C(15, 10, 10), D(50, 200, 60). Objectives: minimize IC50 and clearance, maximize solubility. Which compounds are Pareto-optimal?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 37214, "timestamp": "2026-02-09T08:00:38.502087+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-07", "question_id": "OPT-PEP-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "peptide", "question_text": "Cyclization improves a peptide’s protease stability but reduces affinity because the ring distorts the bioactive geometry. What optimization lever can restore affinity while keeping most of the stability gain, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 19659, "timestamp": "2026-02-09T08:03:09.875601+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-06", "question_id": "SAR-SM-06", "pair_id": "SAR-06", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A kinase inhibitor relies on a heteroaromatic ring to form two hinge hydrogen bonds (one acceptor and one donor). What is the most likely potency effect of replacing that heteroaromatic ring with a phenyl ring at the same position, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Significant potency loss—typically 10- to >1000-fold (ΔΔG ≈ 2–6 kcal/mol).**\n\n**Why", "latency_ms": 15292, "timestamp": "2026-02-09T08:03:28.167959+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-08", "question_id": "GEN-PEP-08", "pair_id": "GEN-08", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In structure-conditioned peptide design for a binding groove, what is typically held fixed vs optimized (backbone vs side chains), and what quantitative structural metric can verify that the designed peptide matches the intended fold?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 13586, "timestamp": "2026-02-09T08:05:50.503055+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-09", "question_id": "GEN-SM-09", "pair_id": "GEN-09", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "List four quantitative metrics commonly used to evaluate small-molecule generative models and briefly state what each measures.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Here are four standard quantitative metrics used to evaluate generative models for small molecules:\n\n1. **Validity**: The percentage of generated structures that are chemically valid (e.g., correct valency, no chemically impossible bonds, proper aromaticity). Typically reported as 0–100%, with high-performing models achieving >90%.\n\n2. **Uniqueness**: The percentage of valid generated molecules that are distinct from one another (cal", "latency_ms": 19313, "timestamp": "2026-02-09T08:06:12.817044+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-07", "question_id": "OPT-SM-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "Adding a fluorine to block a metabolic soft spot increases cLogP from 2.5 to 3.5. What developability risk commonly increases as cLogP rises by ~1 unit, and name one mitigation approach that does not remove the fluorine.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 12471, "timestamp": "2026-02-09T08:08:29.547934+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-03", "question_id": "GEN-PEP-03", "pair_id": "GEN-03", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "A peptide binder design strategy fixes a short epitope (e.g., 4 residues) and generates sequences by varying flanking positions. Why can this improve success rates, and what constraint is commonly applied to keep candidates developable?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 34266, "timestamp": "2026-02-09T08:11:08.885448+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-05", "question_id": "GEN-SM-05", "pair_id": "GEN-05", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You condition a generator to maximize a QSAR-predicted property (e.g., potency) using classifier guidance. What is a common failure mode of this approach, and what is one practical way to detect it?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 17600, "timestamp": "2026-02-09T08:13:54.899561+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-07", "question_id": "ASSAY-SM-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "Three analogs have (IC50 nM, kinetic solubility µM): A(30, 2), B(80, 50), C(20, 0.5). If you require IC50 ≤ 50 nM and solubility ≥ 5 µM for the next round, which analog best meets criteria and what is the most logical next experimental step?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 13370, "timestamp": "2026-02-09T08:16:14.847503+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-09", "question_id": "OPT-SM-09", "pair_id": "OPT-09", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A baseline inhibitor has IC50 = 1.0 µM. Substitution A gives IC50 = 0.30 µM, substitution B gives IC50 = 0.20 µM, and the double substitution AB gives IC50 = 0.020 µM. Under a multiplicative (log-additive) model, what IC50 would you predict for AB, and does the observation indicate positive epistasis (synergy)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Under a multiplicative model, the predicted IC50 for the double substitution AB is **0.060 µM** (60 nM).\n\n**Calculation:**\n- Fold improvement for A: 1.0 µM / 0.30 µM = 3.3-fold\n- Fold improvement for B: 1.0 µM / 0.20 µM = 5.0-fold  \n- Predicted combined fold improvement: 3.3 × 5.0 = 16.7-fold\n- Predicted IC50: 1.0 µM / 16.7 = **0.060 µM** (or 1.0 µM × 0.30 × 0.20)\n\n**Epistasis determination:**\n**Yes, this indicates positive epistasis (synergy).** The observed IC50 (0.020 µM) is 3-fold", "latency_ms": 16687, "timestamp": "2026-02-09T08:16:34.535148+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-09", "question_id": "ADMET-PEP-09", "pair_id": "ADMET-09", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "In an in vivo PK study, a peptide shows accelerating clearance over repeated weekly dosing despite similar initial exposure. What two mechanisms can cause this, and what measurements distinguish them?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 20810, "timestamp": "2026-02-09T08:18:59.610607+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-06", "question_id": "ADMET-SM-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A candidate has TPSA = 140 Å², HBD = 3, and is a P-gp substrate. Name two design strategies that can increase oral absorption and briefly explain the mechanism.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 27353, "timestamp": "2026-02-09T08:21:37.877608+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-01", "question_id": "ADMET-PEP-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "What is the typical plasma half-life range for unmodified linear therapeutic peptides, and what are three primary strategies to extend it (include typical timescale changes)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 20947, "timestamp": "2026-02-09T08:24:21.320218+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-07", "question_id": "ADMET-SM-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "Assume hepatic blood flow Qh ≈ 90 L/h. A drug has hepatic clearance CLh = 60 L/h. Compute the extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 15023, "timestamp": "2026-02-09T08:26:55.141718+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-09", "question_id": "ASSAY-SM-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A PK/PD plot of effect vs plasma concentration shows counterclockwise hysteresis (effect lags concentration early and increases later at the same concentration). What does this imply about system dynamics, and what sampling strategy improves model identifiability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 45668, "timestamp": "2026-02-09T08:30:34.966782+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-01", "question_id": "ASSAY-SM-01", "pair_id": "ASSAY-01", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "Define IC50 in a biochemical inhibition assay and state one key assay-condition factor that can shift the measured IC50 without changing true binding affinity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **IC50** (half-maximal inhibitory concentration) is the concentration of an inhibitor that reduces the activity of a target enzyme (or receptor) by 50% under specific experimental conditions. It is an operational measure of apparent potency, distinct from the intrinsic binding affinity (Ki).\n\n**Key assay-condition factor:** **Substrate concentration ([S])**.\n\nFor competitive inhibitors, the relationship is described by the Cheng-Prusoff equation:  \n**IC50 = Ki × (1 + [S]/Km)**\n\nIncreasing the substrate concentration increases the measured IC50 (making the inhibitor appear weaker), whereas decreasing [S] lowers the IC50 (making it appear more potent), even though the true dissociation constant (Ki) remains unchanged.", "latency_ms": 18619, "timestamp": "2026-02-09T08:30:56.586941+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-05", "question_id": "GEN-PEP-05", "pair_id": "GEN-05", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "You condition a peptide generator to maximize predicted activity from an in silico model. What is a common failure mode, and what validation step reduces the risk of selecting ‘adversarial’ sequences?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " A common failure mode is **reward hacking (or model exploitation)**: the generator discovers sequences that maximize the in silico score by exploiting artifacts, biases, or spurious correlations in the specific predictive model (e.g., memorized training patterns, feature leakage, or physically implausible conformations that the scoring function mishandles), rather than genuine structure–activity relationships. These “adversarial” peptides often possess chemically unreasonable features (e.g., extreme hydrophobicity, repetitive motifs, or steric clashes) that trigger false-positive predictions.\n\nThe key validation step is **ensemble consensus scoring** (or model disagreement analysis). By evaluating generated candidates with multiple, diverse models (e.g., combining a physics-based docking score, a graph neural network, and a transformer-based affinity predictor) and filtering for sequences that rank highly across the ensemble (e.g., top 10% in ≥3 distinct architectures), you reduce the risk of selecting sequences that game a single predictor. Additional safeguards include **applicability domain (AD) filters** (", "latency_ms": 37058, "timestamp": "2026-02-09T08:31:36.646171+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-02", "question_id": "ASSAY-PEP-02", "pair_id": "ASSAY-02", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A hemolysis assay for an antimicrobial peptide yields a steep dose–response with Hill slope ~3. Give a mechanistic interpretation consistent with peptide membrane-disruption behavior.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " A Hill slope of ~3 indicates strong positive cooperativity, consistent with a **multimeric pore-formation mechanism** requiring the cooperative assembly of approximately 3 peptide molecules to produce membrane disruption.\n\n**Mechanistic interpretation:**\n\n1.  **Oligomeric stoichiometry:** The value suggests that the lytic unit is likely a trimer or tetramer. In the **barrel-stave** or **toroidal pore** models, individual peptide monomers bind to the membrane surface and then undergo a cooperative insertion step where 3–4 peptides aggregate to form a stable, water-filled transmembrane pore. The steep sigmoidicity reflects the sharp transition that occurs once the local peptide concentration exceeds the threshold necessary for nucleation of these oligomeric pores.\n\n2.  **Positive cooperativity in membrane insertion:** Initial peptide binding may induce membrane thinning or curvature stress, increasing the affinity of the membrane for subsequent peptide molecules. This creates a \"snowball\" effect where binding facilitates further binding, generating the observed steep dose-response once a critical peptide-to-lipid ratio (~0.1–0.5 for many AMPs) is surpassed.\n\n3.  **Threshold phenomenon (Carpet model variant):** Even in non-pore carpet mechanisms, a Hill slope >1 can indicate that multiple peptides must simultaneously engage the outer leaflet to overcome the bilayer's elastic modulus and trigger micellization or catastrophic membrane failure.\n\n**Note:** While the Hill coefficient often approximates the number of ligand molecules required for activation, it reflects the **minimal functional oligomeric state** rather than precise stoichiometry. A slope of ~3 effectively rules out simple monomeric detergent-like action (nH ≈ 1) and strongly supports a cooperative, multi-hit mechanism for membrane permeabilization.", "latency_ms": 46904, "timestamp": "2026-02-09T08:32:26.550888+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-04", "question_id": "ADMET-SM-04", "pair_id": "ADMET-04", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A small molecule has systemic clearance CL = 30 L/h and volume of distribution Vd = 300 L in humans. Estimate the terminal half-life and interpret what a Vd this large typically implies about tissue distribution.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Terminal half-life:**  \nUsing \\( t_{1/2} = \\frac{0.693 \\times V_d}{CL} \\):\n\n\\[\nt_{1/2} = \\frac{0.693 \\times 300\\ \\text{L}}{30\\ \\text{L/h}} \\approx \\mathbf{6.9\\ \\text{hours}}\\ (\\text{or roughly } \\mathbf{7\\ \\text{h}})\n\\]\n\n**Interpretation of \\( V_d = 300\\ \\text{L} \\):**  \nThis value is **~7–8× total body water** (~40–42 L in a 70 kg adult) and indicates **extensive tissue distribution**. It implies the drug is highly lipophilic or binds avidly to tissue proteins/phospholipids (e.g., in adipose, muscle, or organ parenchyma), such that only a small fraction of the total drug in the body remains in plasma at equilibrium. Consequently, plasma concentrations will be low relative to the total amount of drug present systemically.", "latency_ms": 28831, "timestamp": "2026-02-09T08:32:58.383066+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-04", "question_id": "ASSAY-PEP-04", "pair_id": "ASSAY-04", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A peptide is degraded by a protease with apparent first-order rate constant k = 0.023 min^-1 (measured under pseudo-first-order conditions). Compute the degradation half-life and interpret what this means for a 2-hour incubation assay.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Half-life calculation**\n\nFor first-order kinetics:  \n$$t_{1/2} = \\frac{\\ln(2)}{k} = \\frac{0.693}{0.023\\ \\text{min}^{-1}} \\approx \\mathbf{30\\ \\text{minutes}}\\ (\\text{range: 30–31 min})$$\n\n**Interpretation for a 2‑hour (120‑min) assay**\n\n- **Duration relative to half‑life:** 120 min ÷ 30 min ≈ **4 half‑lives**.\n- **Remaining peptide:** Fraction remaining = $e^{-kt} = e^{-0.023 \\times 120} \\approx e^{-2.76} \\approx \\mathbf{6\\%}$ (range: 6–7 %).  \n  Thus, **~94 % of the peptide is degraded** by the end of the incubation.\n\n**Practical implications**\n\n1. **Substrate depletion:** If the peptide is a substrate for an enzymatic reaction, its concentration drops >90 % over the assay window, violating steady‑state assumptions and making initial‑rate determination unreliable unless the reaction is quenched much earlier (e.g., within one half‑life, ≤30 min).\n\n2. **Analytical stability:** If the peptide is the analyte being quantified, the signal decays exponentially; samples must be processed immediately or the protease inhibited to prevent ex vivo degradation.\n\n3. **Pharmacokinetic relevance:** A 30‑min half‑life suggests rapid systemic clearance (similar to many therapeutic peptides in plasma), implying limited exposure in vivo and a need for formulation or chemical stabilization (e.g., N‑methylation, cyclization, or D‑amino‑acid substitution) for drug development.", "latency_ms": 35482, "timestamp": "2026-02-09T08:33:36.866143+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-07", "question_id": "ADMET-PEP-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Assume renal plasma flow Qr ≈ 45 L/h. A peptide has renal clearance CLr = 5 L/h. Compute extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 22346, "timestamp": "2026-02-09T08:36:36.889207+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-05", "question_id": "SAR-SM-05", "pair_id": "SAR-05", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s secondary amide NH donates a hydrogen bond to the target (N–O distance ~2.9 Å) and is critical for potency. What is the expected potency effect of replacing that amide with an ester at the same position, and what other property often changes in parallel?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 19796, "timestamp": "2026-02-09T08:39:22.320847+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-04", "question_id": "GEN-PEP-04", "pair_id": "GEN-04", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Phage display yields enrichment values across panning rounds. How can enrichment be used as a training signal for peptide sequence generation, and what experimental bias must be considered?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Using Enrichment as a Training Signal**\n\nEnrichment values (typically calculated as the ratio of post-selection phage titer to input titer, or normalized sequence frequencies between rounds) serve as quantitative fitness proxies in machine learning pipelines:\n\n1.  **Regression Targets:** Enrichment ratios (often log-transformed, ranging from 0.1 to >1000× across 3–4 panning rounds) train supervised models (CNNs, Transformers, or RNNs) to predict binding potential from sequence. Models learn to map sequence space to continuous fitness landscapes.\n2.  **Generative Guidance:** In variational autoencoders (VAEs) or diffusion models, enrichment values weight the loss function or condition the latent space, steering generation toward high-fitness regions.\n3.  **Reinforcement Learning:** Enrichment provides the reward signal for policy gradient methods (e.g., REINFORCE), where the agent generates sequences and receives reward proportional to predicted or measured enrichment.\n4.  **Active Learning:** Enrichment uncertainties guide iterative library design, prioritizing sequences at the predicted fitness boundary for experimental validation.\n\n**Critical Experimental Biases**\n\nEnrichment is a composite signal conflating binding affinity with multiple confounding factors that must be explicitly modeled or experimentally controlled:\n\n*   **Amplification Bias:** During *E. coli* amplification between rounds (typically 10²–10⁴-fold expansion), sequence-dependent differences in phage replication rates (due to codon usage, toxicity of displayed peptides, or proteolytic degradation) can create 2–10× artificial enrichment unrelated to target binding.\n*   **Avidity vs. Affinity:** Multivalent display (3–5 copies of pIII fusion per virion) means enrichment often reflects avidity (apparent K_D in nM–μM range) rather than monoval", "latency_ms": 19684, "timestamp": "2026-02-09T08:39:45.005467+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-10", "question_id": "GEN-PEP-10", "pair_id": "GEN-10", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "You expand a peptide generator to include several non-natural amino acids. What must be updated in the model representation and in downstream scoring to keep generation physically and chemically coherent?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " To incorporate non-natural amino acids (UAAs) into a peptide generative model while maintaining physical and chemical coherence, you must update both the **representation layer** and **scoring functions** as follows:\n\n## 1. Model Representation Updates\n\n**Vocabulary & Tokenization**\n- Expand the token dictionary to include new 3-letter codes (e.g., \"NLE\" for norleucine, \"BPA\" for *p*-benzoyl-L-phenylalanine) or SMILES/SELFIES substructures\n- Add stereochemistry flags (D- vs. L-configuration, R/S centers) to distinguish enantiomers\n\n**Feature Embeddings**\n- Initialize/train new embedding vectors for each UAA in the latent space\n- Update atomic feature vectors to include new elements (e.g., fluorine in trifluoromethyl-phenylalanine) or hybridization states (sp³ carbons in β-amino acids)\n- Extend graph neural network node features to account for novel side chain topologies (e.g., cyclic constraints in 1-aminocyclopentane-1-carboxylic acid)\n\n**Geometric Priors**\n- Update rotamer libraries (χ angle distributions)", "latency_ms": 24131, "timestamp": "2026-02-09T08:40:12.136943+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-02", "question_id": "OPT-PEP-02", "pair_id": "OPT-02", "category": "Optimization Approaches", "domain": "peptide", "question_text": "Define a Pareto-optimal set for peptides optimized simultaneously for higher potency, higher serum stability, and lower hemolysis. What does it mean for one peptide to dominate another?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In multi-objective peptide optimization, the **Pareto-optimal set** (or Pareto front) is the collection of peptides for which **no single objective can be improved without worsening at least one other objective**. \n\nFor your three objectives—**maximizing potency", "latency_ms": 12898, "timestamp": "2026-02-09T08:40:55.475614+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-08", "question_id": "OPT-SM-08", "pair_id": "OPT-08", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In batch Bayesian optimization where you choose 20 compounds per cycle, why is within-batch diversity important, and name one method to enforce it during selection?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Within-batch diversity is critical for three reasons:\n\n1. **Information efficiency**: Selecting 20 structurally similar compounds yields redundant data, wasting experimental resources that could explore distinct regions of chemical space. Diverse batches maximize information gain per cycle, accelerating model convergence.\n\n2. **Risk mitigation**: If a single scaffold has inherent liabilities (e.g., metabolic instability, toxicity), a homogeneous batch risks simultaneous failure of all", "latency_ms": 14891, "timestamp": "2026-02-09T08:41:43.828575+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-03", "question_id": "GEN-SM-03", "pair_id": "GEN-03", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "In fragment-based de novo design, why does starting from known fragments often improve hit rates, and what constraint is commonly applied to keep designs synthesizable?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Starting from **known fragments** improves hit rates because these fragments have validated binding modes and established ligand efficiency (typically LE > 0.3 kcal/mol per heavy atom). They serve as \"anchors\" with proven complementarity to the target binding site, reducing the chemical search space from ~10^60 possible drug-like molecules to growable/linked subsets. Empirically, fragment-derived compounds show hit rates of **10–30%** in follow-up assays versus <1% for random HTS compounds.\n\nTo maintain synthesizability, designs are commonly constrained by **synthetic accessibility scores** (e.g., SAscore, SYBA, or SCScore) with thresholds typically **< 4.0–5.0** (on normalized scales), or more rigorously by **reaction-based enumeration**—allowing only bond formations corresponding to robust, known transformations (e.g., amide coupling, Suzuki-Miyaura, SNAr) and requiring that constituent fragments be **commercially available** (e.g., Enamine REAL database, >10^7 building blocks). Advanced systems apply **retrosynthetic analysis** (e.g., AiZynthFinder, CASP tools) to verify 1–3 step synthetic routes from stock reagents before scoring a design as valid.", "latency_ms": 34803, "timestamp": "2026-02-09T08:42:21.632444+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-10", "question_id": "ASSAY-SM-10", "pair_id": "ASSAY-10", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "An HTS assay has positive-control mean signal μp = 10 with SD σp = 2, and negative-control mean μn = 100 with SD σn = 5. Compute Z' factor and interpret assay quality.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Calculation:**\n\nThe Z′ factor is calculated as:\n\n$$Z' = 1 - \\frac{3\\sigma_p + 3\\sigma_n}{|\\mu_p - \\mu_n|}$$\n\nSubstituting the values:\n- $|\\mu_p - \\mu_n| = |10 - 100| = 90$\n- $3\\sigma_p + 3\\sigma_n = 3(2) + 3(5) = 6 + 15 = 21$\n\n$$Z' = 1 - \\frac{21}{90} = 1 - 0.233 = \\mathbf{0.77}$$\n\n(or exactly **0.767**)\n\n**Interpretation:**\n\nA Z′ factor of **0.77 indicates an excellent assay**. \n\nStandard interpretation thresholds:\n- **Z′ ≥ 0.5**: Excellent assay quality (large dynamic range, low variability)\n- **0 < Z′ < 0.5**: Marginal/poor separation (may work but with high false positive/negative rates)\n- **Z′ ≤ 0**: Unusable assay (controls overlap significantly)\n\nWith Z′ = 0.77, the assay shows robust separation between positive and negative controls (90-unit signal window) relative to the control variability, making it suitable for high-throughput screening.", "latency_ms": 29541, "timestamp": "2026-02-09T08:42:54.174232+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-07", "question_id": "GEN-SM-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Give three commonly used synthesizability/developability filters applied to generated small molecules and provide a typical numeric threshold for at least one of them.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 8310, "timestamp": "2026-02-09T08:45:33.950145+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-03", "question_id": "ASSAY-PEP-03", "pair_id": "ASSAY-03", "category": "Assay Interpretation", "domain": "peptide", "question_text": "An antimicrobial peptide has MIC = 2 µg/mL against a bacterium and hemolysis HC50 = 200 µg/mL. Compute the therapeutic index (HC50/MIC) and interpret it.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Calculation:**\n\nTherapeutic Index (TI) = HC50 / MIC = 200 µg/mL ÷ 2 µg/mL = **100**\n\n**Interpretation:**\n\nA therapeutic index of **100** indicates that the antimicrobial peptide is **100-fold more potent** against the target bacterium than it is toxic to mammalian red blood cells (hemolysis). \n\n**Context:**\n- **TI > 10**: Generally considered minimally acceptable for antimicrobial peptide development\n- **TI = 100**: Represents **good selectivity** and a reasonable safety margin, suggesting the peptide can effectively inhibit bacterial growth at concentrations far below those causing host cell toxicity\n- **TI > 1000**: Considered excellent/selective\n\nWith a TI of 100, this peptide demonstrates promising drug-like properties with substantial separation between antimicrobial efficacy and hemolytic risk, though other toxicity parameters (e.g., cytotoxicity against nucleated mammalian cells, in vivo stability, immunogenicity) would need evaluation for complete safety profiling.", "latency_ms": 4785, "timestamp": "2026-02-09T08:45:41.736597+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-07", "question_id": "SAR-SM-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A phenyl ring in a lead compound occupies a hydrophobic pocket in both the intended target and a close off-target homolog. Only the intended target has a nearby Ser OH positioned to hydrogen-bond to a ring heteroatom. What is the expected effect on target potency and selectivity of replacing phenyl with a 3-pyridyl ring (introducing one ring nitrogen), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 7332, "timestamp": "2026-02-09T08:47:29.218415+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-09", "question_id": "ADMET-SM-09", "pair_id": "ADMET-09", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "How do you experimentally distinguish reversible CYP inhibition from mechanism-based (time-dependent) inhibition in vitro, and why does time-dependent inhibition elevate clinical DDI risk?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Experimental Distinction**\n\nThe standard approach is the **IC50 shift assay** with and without NADPH-dependent pre-incubation:\n\n1.  **Pre-incubation Protocol**: Incubate the test compound (7-10 concentrations) with human liver microsomes (HLM) or recombinant CYP enzyme **± NADPH** for **30–60 min** at 37°C. Then add probe substrate (e.g., midazolam for CYP3A4) + NADPH to measure residual enzyme activity.\n    *   **Reversible inhibition**: IC50 values remain constant regardless of pre-incubation time (fold-shift typically **<1.5**).\n    *   **Time-dependent inhibition (TDI)**: IC50 decreases (potency increases) with pre-incubation, yielding a **≥1.5-fold to 2-fold IC50 shift** (e.g., IC50 shifts from 10 µM with no pre", "latency_ms": 10321, "timestamp": "2026-02-09T08:48:02.773523+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-02", "question_id": "ADMET-PEP-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A linear peptide is rapidly cleaved by trypsin-like proteases at a Lys site (cleavage after Lys). Name two peptide modifications that typically reduce this cleavage and explain why serum stability increases (include a typical qualitative timescale change).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 11458, "timestamp": "2026-02-09T08:49:57.095934+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-10", "question_id": "ADMET-PEP-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Why do small peptides (e.g., 1–5 kDa) often clear rapidly via the kidney, and how does increasing hydrodynamic size (e.g., PEGylation) reduce this clearance?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 9653, "timestamp": "2026-02-09T08:51:47.388201+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-01", "question_id": "GEN-SM-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "In SMILES-based molecular generation, name three necessary validity conditions a generated string must satisfy to correspond to a chemically valid molecule.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 9148, "timestamp": "2026-02-09T08:53:39.609945+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-10", "question_id": "SAR-SM-10", "pair_id": "SAR-10", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A biaryl inhibitor rapidly interconverts between two atropisomers, but only one atropisomer fits the binding pocket. What design change is most likely to increase potency and selectivity, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The most effective design change is **introducing steric bulk (e.g., methyl, halogen, or isopropyl substituents) at the ortho-positions of the biaryl linkage** to raise the rotational energy barrier and \"lock\" the active atropisomer.\n\n**Why this increases potency:**\n- **Maximizes target engagement:** Rapid interconversion means only ~50% of molecules occupy the active atropisomer at equilibrium. Locking the configuration ensures 100% of the compound is competent for binding, effectively doubling the functional concentration.\n- **Reduces entropic penalty:** Pre-organizing the molecule into the bioactive conformation eliminates the conformational entropy cost (ΔS) paid upon binding, improving binding affinity (ΔG = ΔH - TΔS). A typical gain is **1-3 kcal/mol** in binding free energy, corresponding to **2- to 100-fold** increases in potency.\n\n**Why this increases selectivity:**\n- **Eliminates off-target binding:** The \"inactive\" atropisomer may bind promiscuously to other targets or allosteric sites. Locking prevents its existence, reducing off-target liability.\n- **Enables chiral discrimination:** Stabilizing the atropisomer (rotational barrier **>20–25 kcal/mol**) allows isolation of the single enantiomer (atropisomer), which often shows **>10–100-fold** selectivity over the antipode in cellular assays.\n\n**Key constraint:** The substituents must be large enough to prevent rotation (halting interconversion on the timescale of the assay/biological system) but not so large as to sterically clash with the binding pocket itself.", "latency_ms": 7369, "timestamp": "2026-02-09T08:55:26.618918+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-04", "question_id": "OPT-SM-04", "pair_id": "OPT-04", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In Bayesian optimization for molecules, what does Expected Improvement (EI) favor, and why is predictive uncertainty required for principled exploration?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In Bayesian optimization (BO) for molecules, **Expected Improvement (EI) favors candidates with either high predicted property values (exploitation) or high predictive uncertainty (exploration)**, optimally balancing both via the acquisition function:\n\n$$\\text{EI}(x) = (\\mu(x) - f^*)\\Phi(Z) + \\sigma(x)\\phi(Z)$$\n\nwhere $\\mu(x)$ is the predicted mean, $\\sigma(x)$ is the predictive standard deviation, $f^*$ is the current best observed value, $Z = (\\mu(x) - f^*)/\\sigma(x)$, and $\\Phi/\\phi$ are the standard normal CDF/PDF.\n\n**Why predictive uncertainty is required for principled exploration:**\n\n1. **Automatic exploration-exploitation trade-off**: Without $\\sigma(x)$, the optimizer would greedily select molecules with highest predicted activity, ignoring whether those predictions are reliable. Uncertainty explicitly quantifies doubt, forcing exploration of chemical subspaces (e.g., novel scaffolds, unusual functional groups) where the surrogate model (often a Gaussian Process or neural network) lacks training data.\n\n2. **Avoiding spurious exploitation**: In vast chemical spaces ($\\sim10^{60}$ drug-like molecules), machine learning models confidently mispredict properties for out-of-distribution structures. Predictive uncertainty prevents the", "latency_ms": 124037, "timestamp": "2026-02-09T08:57:33.657036+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-01", "question_id": "OPT-PEP-01", "pair_id": "OPT-01", "category": "Optimization Approaches", "domain": "peptide", "question_text": "What is an alanine scan in peptide optimization, and what does a large activity loss upon Ala substitution at a position imply about that residue’s role?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " An **alanine scan** is a systematic mutagenesis strategy in which each amino acid residue in a peptide (or protein) is individually substituted with alanine to determine the contribution of specific side chains to biological activity (e.g., binding affinity, receptor activation, or enzymatic function). Alanine is chosen because its methyl side chain (–CH₃) is small, chemically inert, and removes all atoms beyond the Cβ carbon, thereby eliminating specific side-chain interactions (hydrogen bonding, electrostatic contacts, or hydrophobic packing) while minimally perturbing the backbone conformation.\n\n**Implication of large activity loss:**\nA significant decrease in activity (typically >5- to >100-fold loss in potency, depending on the assay) upon Ala substitution indicates that the original residue is a **\"hot spot\"** critical for function. Specifically, this implies:\n\n*   **Specific binding interactions:** The native side chain likely forms essential hydrogen bonds, salt bridges, or hydrophobic contacts with the target that cannot be accommodated by the small methyl group of alanine.\n*   **Steric or conformational constraints:** The residue may be required for maintaining the bioactive conformation through steric packing or restricting backbone flexibility; replacing it with the smaller alanine induces conformational disorder or collapse.\n*   **Functional specificity:** The loss is not merely due to bulk removal but to the loss of specific chemical functionality (e.g., a charged Lys or Glu, or an aromatic Tyr).\n\nConversely, retention of activity suggests the residue acts primarily as a structural spacer or is located in a non-critical region.", "latency_ms": 61064, "timestamp": "2026-02-09T08:58:37.722037+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-01", "question_id": "OPT-SM-01", "pair_id": "OPT-01", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "What is matched molecular pair (MMP) analysis, and how is it used to prioritize substitutions during lead optimization?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Matched Molecular Pair (MMP) analysis** is a cheminformatics method that identifies pairs of molecules differing by only a single, localized structural transformation (e.g., H → CH₃, Cl → F, or phenyl → pyridyl) at the same position, with identical \"context\" (surrounding scaffold). \n\n## Core Methodology\nAn MMP consists of two compounds (R-X and R-Y) sharing a common core (R) but differing at one attachment point (X vs. Y). Analysis involves mining historical databases (e.g., >10,000–100,000 compounds) to extract transformations and calculating the mean change (Δ) in biological or physicochemical properties:\n\n- **Activity shifts**: ΔpIC₅₀, ΔpEC₅₀  \n- **ADMET properties**: ΔlogP (typically +0.5 per added CH₂), ΔlogD, Δsolubility, ΔhERG IC₅₀, ΔCYP inhibition  \n- **Pharmacokinetics**: ΔCL, Δt½, ΔF (% bioavailability)\n\n## Prioritization in Lead Optimization\nMMP analysis prioritizes substitutions through **transformation rules** supported by statistical significance:\n\n1. **Quantitative Prediction**: If a transformation (e.g., *ortho*-Cl → *ortho*-CF₃ on a phenyl ring) historically yields ΔpIC₅₀ = +0.8 ± 0.3 log units across ≥3–5 distinct scaffolds (n≥3 is a common threshold for reliability), it is prioritized for synthesis over transformations with negligible or variable effects.\n\n2. **Activity Cliff Detection**: MMPs revealing large potency shifts (|ΔpIC₅₀| > 1.0) with minimal structural change flag \"hot spots\" for critical interactions, guiding focused SAR exploration.\n\n3. **Property Balancing**: Multiparameter optimization uses MMP \"swap rules\" to improve one property without degrading others. For example:\n   - Replacing a piperidine with a piperazine typically reduces logP by ~0.4–0.6 units while maintaining basicity\n   - Adding a para-F to an aniline often improves metabolic stability (reduces CYP2D6 inhibition by ~2–3-fold) with minimal steric impact\n\n4. **Context-Specific Guidance**: Analysis restricted to radius-1 or radius-2 environments (atoms 1–2 bonds from the attachment point) distinguishes scaffold-dependent effects from", "latency_ms": 39378, "timestamp": "2026-02-09T08:59:20.100751+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-04", "question_id": "SAR-PEP-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds its target as an α-helix, and residue i is buried in a helix-dependent interface. What is the most likely effect on activity of substituting that residue from an L-amino acid to the corresponding D-amino acid, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 103986, "timestamp": "2026-02-09T09:05:37.094599+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-08", "question_id": "ADMET-SM-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A basic drug has pKa = 9.5 and cLogP = 3.5. At intestinal pH 6.5, approximately what fraction is un-ionized, and what does that imply for passive permeability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 53139, "timestamp": "2026-02-09T09:08:21.657800+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-10", "question_id": "ASSAY-PEP-10", "pair_id": "ASSAY-10", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A peptide screening assay has positive-control mean μp = 20 with SD σp = 3, and negative-control mean μn = 100 with SD σn = 6. Compute Z' factor and interpret assay quality.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Calculation**\n\nThe Z′ factor is calculated as:\n\n\\[\nZ' = 1 - \\frac{3\\sigma_p + 3\\sigma_n}{|\\mu_p - \\mu_n|}\n\\]\n\nSubstituting the values:\n- \\(|\\mu_p - \\mu_n| = |20 - 100| = 80\\)\n- \\(3\\sigma_p + 3\\sigma_n = 3(3) + 3(6) = 9 + 18 = 27\\)\n\n\\[\nZ' = 1 - \\frac{27}{80} = 1 - 0.3375 = \\mathbf{0.66}\n\\]\n\n**Interpretation**\n\nA Z′ factor of **0.66** indicates **excellent assay quality", "latency_ms": 144176, "timestamp": "2026-02-09T09:10:48.835018+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-04", "question_id": "GEN-SM-04", "pair_id": "GEN-04", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "What is reaction-aware molecular generation, and why does it typically produce a higher fraction of synthesizable proposals than unconstrained SMILES generation?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Reaction-aware molecular generation** is a computational approach that designs molecules by explicitly simulating chemical reactions—either by assembling building blocks through valid synthetic transformations or by optimizing structures within the constraints of known reaction mechanisms and available starting materials. Unlike string-based methods, it treats synthesis as an integral part of the generative process, often using reaction templates (e.g., from databases like USPTO or Reaxys), forward-reaction prediction models, or retrosynthetic constraints.\n\n**Why it produces higher fractions of synthesizable proposals:**\n\n1. **Construction from validated synthons**  \n   These methods assemble molecules from commercially available or pre-validated building blocks (e.g., boronic acids, amines, aldehydes) using robust, well-characterized reactions (e.g., Suzuki–Miyaura couplings, amide bond formations). This ensures the product inherently possesses a retrosynthetic disconnections strategy, whereas unconstrained SMILES generation creates structures *de novo* without regard to starting materials or bond-forming feasibility.\n\n2. **Enforcement of chemical grammar**  \n   Unconstrained SMILES generators (e.g., char-RNNs or GPT models) produce 5–20% syntactically invalid strings and a significant fraction of chemically unstable or impossible structures (e.g., pentavalent carbons, unrealistic ring strain). Reaction-aware generation maintains valence rules and reaction mechanisms by construction, typically achieving >95% chemical validity and ensuring ring systems and functional groups are compatible with real synthetic chemistry.\n\n3. **Implicit optimization of synthetic accessibility**  \n   By restricting the chemical space to", "latency_ms": 52263, "timestamp": "2026-02-09T09:11:54.876343+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-02", "question_id": "SAR-SM-02", "pair_id": "SAR-02", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A carboxylate on a small molecule forms a salt bridge to a Lys side chain (N–O distance ~2.8–3.0 Å) and is required for activity. What is the most likely effect on potency if you convert the carboxylic acid to a methyl ester, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Most likely effect:** A substantial decrease in potency (typically **10- to >100-fold**, potentially abolishing activity).\n\n**Reasoning:**\n\n1.  **Loss of the salt bridge:** At physiological pH, the Lys side chain is protonated (–NH₃⁺, pKa ~10.5) and the carboxylic acid is deprotonated (–COO⁻, pKa ~4–5). The 2.8–3.0 Å N–O distance indicates a strong, charge-assisted hydrogen bond (salt bridge) contributing approximately **1–3 kcal/mol** (up to", "latency_ms": 40298, "timestamp": "2026-02-09T09:12:38.174853+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-06", "question_id": "GEN-PEP-06", "pair_id": "GEN-06", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Name two generation-time techniques that increase diversity of generated peptide sequences and one quantitative diversity metric commonly used for sequences.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 47073, "timestamp": "2026-02-09T09:18:11.397069+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-09", "question_id": "SAR-SM-09", "pair_id": "SAR-09", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A tertiary amine (pKa ~9) forms a salt bridge to an Asp in the binding site (N–O distance ~2.8 Å). You replace the tertiary amine with an amide at the same position. What is the most likely potency effect and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 118698, "timestamp": "2026-02-09T09:25:56.325637+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-10", "question_id": "ADMET-SM-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "What approximate molecular-weight threshold is commonly associated with increased biliary excretion for small molecules, and what other physicochemical features favor biliary vs renal elimination?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 850, "timestamp": "2026-02-09T09:30:29.728611+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-10", "question_id": "GEN-SM-10", "pair_id": "GEN-10", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You expand a molecular generator to include non-standard charged fragments (new tokens not seen in the original training set). What two components must be updated to keep generation chemically consistent and valid?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 67272, "timestamp": "2026-02-09T09:36:45.861753+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-05", "question_id": "OPT-SM-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A lead compound is cleared rapidly due to oxidative N-dealkylation of a tertiary amine. Propose two structural changes that often reduce this clearance while preserving a basic center, and explain why they work.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 67439, "timestamp": "2026-02-09T09:42:11.123196+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-02", "question_id": "ADMET-SM-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A benzylic CH2 is identified as the major CYP oxidation soft spot (rapid benzylic hydroxylation). Name one structural change that typically reduces this metabolism and explain the mechanism (include a typical magnitude of intrinsic clearance reduction).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 76294, "timestamp": "2026-02-09T09:48:49.740047+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-02", "question_id": "OPT-SM-02", "pair_id": "OPT-02", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In multi-parameter optimization (MPO) for small molecules, how does a weighted desirability function combine objectives, and what is the limitation when objectives conflict?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In multi-parameter optimization (MPO), weighted desirability functions combine objectives by first scaling each property (e.g., potency, logP, solubility) to a common 0–1 scale using individual desirability functions (*d*ᵢ), where 0 = unacceptable and 1 = ideal. These are aggregated using a weighted geometric mean:\n\n**D = (Π *d*ᵢ^wᵢ)^(1/Σwᵢ)**\n\nwhere *w*ᵢ represents the relative importance of parameter *i*. The overall desirability *D* (0–1) enables compound ranking.\n\n**Limitation with conflicting objectives:**\nThe primary limitation is **compensation masking**: high desirability in one objective can mathematically compensate for unacceptable performance in another, potentially selecting compounds that violate critical constraints. For example, with equal weights (*w* = 1), a compound with excellent potency (*d* = 1.0) but poor aqueous sol", "latency_ms": 101100, "timestamp": "2026-02-09T09:50:33.840654+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-03", "question_id": "ADMET-SM-03", "pair_id": "ADMET-03", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "What physicochemical profile is commonly associated with hERG liability, and what in vitro hERG IC50 threshold is often treated as a significant flag for follow-up?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Physicochemical Profile Associated with hERG Liability**\n\nhERG blockers typically share a \"pharmacophore\" consisting of a **protonatable basic nitrogen** (pKₐ usually **> 7.5–8.0**) flanked by **lipophilic/hydrophobic groups** (often aromatic rings). Key physicochemical flags include:\n\n*   **Basicity:** A centrally located basic amine (often tertiary) that is positively charged at physiological pH.\n*   **High lipophil", "latency_ms": 21678, "timestamp": "2026-02-09T09:52:15.948578+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-03", "question_id": "SAR-PEP-03", "pair_id": "SAR-03", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A linear 10-mer peptide binds a target in a compact turn-like conformation. What is the most likely effect of head-to-tail cyclization on potency and why (assume cyclization does not directly block a key contact residue)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 34696, "timestamp": "2026-02-09T09:55:38.503643+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-04", "question_id": "SAR-SM-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A chiral secondary alcohol is positioned so that only the (S)-enantiomer can donate a hydrogen bond to an Asp residue; the (R)-enantiomer points the substituent into a tight hydrophobic cleft causing steric clash. Which enantiomer is expected to be more potent, and what magnitude of potency difference is commonly observed in such cases?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 47245, "timestamp": "2026-02-09T09:59:36.082918+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-04", "question_id": "OPT-PEP-04", "pair_id": "OPT-04", "category": "Optimization Approaches", "domain": "peptide", "question_text": "How can Bayesian optimization be applied to peptide sequences using embeddings, and what does EI do in that setting?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Bayesian optimization (BO) can be applied to peptide sequences by mapping discrete sequences into a continuous **embedding space** where standard BO operates, then using acquisition functions like Expected Improvement (EI) to guide the search. Here is the specific workflow and role of EI:\n\n## 1. Embedding Peptides for BO\nSince peptides are discrete (sequences of 20 amino acids) and often variable-length, they are first encoded into fixed-dimensional continuous vectors (embeddings, **z** ∈ ℝᵈ, typically **d = 64–1024**):\n\n- **Learned embeddings**: Variational autoencoders (VAEs) or protein language models (e.g., ESM-2, ProtBERT) trained on sequence databases map peptides to latent vectors that capture physicochemical and structural properties.\n- **Hand-crafted embeddings**: Physicochemical descriptors (hydrophobicity, charge, molecular weight) concatenated into feature vectors.\n\nThe BO surrogate model—typically a **Gaussian Process (GP)**—is then trained on the dataset **D = {(zᵢ, yᵢ)}**, where **zᵢ** is the embedding of peptide **i** and **yᵢ** is the experimental property (e.g., binding affinity, IC₅₀, stability).\n\n## 2. Optimization", "latency_ms": 64887, "timestamp": "2026-02-09T10:00:43.970640+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-02", "question_id": "ASSAY-SM-02", "pair_id": "ASSAY-02", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A dose–response curve fit yields a Hill slope of 0.5 (much shallower than 1). Give two mechanistic interpretations relevant to small-molecule assays.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 27244, "timestamp": "2026-02-09T10:04:53.322149+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-10", "question_id": "SAR-PEP-10", "pair_id": "SAR-10", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide bond adjacent to a Pro residue exists as a cis/trans mixture in solution, but only the trans conformer binds the target. What modification is most likely to increase apparent potency, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 30091, "timestamp": "2026-02-09T10:08:28.549182+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-10", "question_id": "OPT-PEP-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "peptide", "question_text": "You have four peptides with (EC50 nM, serum half-life h, hemolysis HC50 µg/mL): A(10, 0.2, 50), B(30, 8, 40), C(15, 2, 200), D(50, 20, 20). Objectives: minimize EC50, maximize half-life, maximize HC50. Which peptides are Pareto-optimal?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 31944, "timestamp": "2026-02-09T10:11:18.741497+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-02", "question_id": "GEN-PEP-02", "pair_id": "GEN-02", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Protein language models trained with a masked-token objective can be used for peptide ‘inpainting’. What does the masked-token objective learn, and why does it enable filling variable positions around a fixed motif?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The **masked-token objective** trains the model to predict randomly masked amino-acid tokens from their surrounding sequence context. Formally, it learns the conditional probability distribution **P(x<sub>i</sub> | x<sub>\\i</sub>)**—the likelihood of an amino acid at position *i* given all other (unmasked) positions.\n\n**What it learns:**\n*   **Contextual dependencies:** Local sequence constraints (e.g., steric hindrance, secondary structure propensities) and long-range co-evolutionary couplings (e.g., contacts that stabilize tertiary structure).\n*   **Physicochemical compatibility:** Implicit rules governing charge, hydrophobicity, and size distributions that maintain protein stability and solubility.\n*   **Evolutionary fitness:** Tolerance patterns for substitutions, effectively approximating the underlying fitness landscape of natural protein families.\n\n**Why this enables inpainting:**\nInpainting exploits the fact that the model was trained to fill “holes” (masked positions) conditioned on visible context", "latency_ms": 45060, "timestamp": "2026-02-09T10:12:06.802350+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-06", "question_id": "ASSAY-SM-06", "pair_id": "ASSAY-06", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound has target IC50 = 200 nM and cellular CC50 (viability) = 20 µM. Compute the in vitro safety window (CC50/IC50) and state one follow-up assay you would run to contextualize the cytotoxicity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Safety window:** 100-fold (or 100×)\n\n**Calculation:**  \nCC50 (20 µM) ÷ IC50 (200 nM = 0.2 µM) = **100**\n\n**Follow-up assay:**  \nRun a **cytotoxicity assay in an isogenic target-knockout (KO) cell line** (or a target-negative parental line). If the CC50 shifts significantly (e.g., ≥5-fold increase) in the absence of the target, the cytotoxicity is likely **on-target** (mechanism-related); if unchanged, it suggests **off-target** toxicity. \n\n*Alternative acceptable answers:* Caspase-3/7 activation assay (to distinguish apoptosis from necrosis), or testing in relevant primary human cells to assess therapeutic index versus transformed cell lines.", "latency_ms": 42053, "timestamp": "2026-02-09T10:13:59.058171+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-01", "question_id": "ADMET-SM-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "State Lipinski’s Rule-of-Five thresholds (MW, cLogP, HBD, HBA) and give two mechanistic reasons why violating multiple thresholds tends to reduce oral exposure.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 40338, "timestamp": "2026-02-09T10:18:07.855815+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-01", "question_id": "SAR-SM-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s para-substituent on a phenyl ring points into a hydrophobic subpocket and sits ~3.2 Å from a protein backbone carbonyl oxygen (geometry compatible with a halogen bond). If the para-methyl analog has IC50 = 200 nM, what is the most likely potency change when replacing para-CH3 with para-Cl, and what is the mechanistic rationale?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 40060, "timestamp": "2026-02-09T10:21:44.743912+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-08", "question_id": "ASSAY-PEP-08", "pair_id": "ASSAY-08", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In an in vivo antibacterial study, increasing peptide dose increases plasma exposure linearly but bacterial load reduction plateaus at ~60% and does not improve further. What does this suggest mechanistically, and what is one follow-up measurement to confirm?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 48917, "timestamp": "2026-02-09T10:26:02.512965+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-09", "question_id": "GEN-PEP-09", "pair_id": "GEN-09", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "List four quantitative metrics commonly used to evaluate peptide sequence generative models and briefly state what each measures.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " 1.  **Perplexity** – Measures the model’s predictive performance by quantifying how well it estimates the probability distribution of the next amino acid in a sequence (lower values indicate better calibration and sequence learning).\n\n2.  **Validity** – The percentage of generated sequences that are chemically legitimate (e.g., contain only standard 20 amino‑acid residues, satisfy length constraints, and lack invalid tokens or stop codons).\n\n3.  **Novelty** – The proportion of generated sequences that are not exact matches (or have <100% identity) to any sequence in the training set, assessing the degree of memorization versus *de novo* generation.\n\n4.  **", "latency_ms": 34458, "timestamp": "2026-02-09T10:28:31.230843+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-07", "question_id": "ASSAY-PEP-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Three peptide variants have (EC50 nM, serum stability t1/2 min): A(30, 15), B(80, 240), C(20, 5). If you require EC50 ≤ 50 nM and serum t1/2 ≥ 60 min for the next round, which variant best meets criteria and what is the most logical next step?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 40085, "timestamp": "2026-02-09T10:31:57.518404+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-07", "question_id": "GEN-PEP-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Give three developability/manufacturability filters applied to generated peptide sequences and provide a typical numeric threshold for at least one (e.g., charge or length).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 24337, "timestamp": "2026-02-09T10:35:17.629946+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-05", "question_id": "ASSAY-PEP-05", "pair_id": "ASSAY-05", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In a mouse efficacy study of a therapeutic peptide dosed weekly, efficacy improves on days 1–3 but wanes by week 3 despite unchanged dosing. Give two plausible assay-linked explanations and name one measurement that distinguishes them.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 83122, "timestamp": "2026-02-09T10:40:44.897188+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-03", "question_id": "ADMET-PEP-03", "pair_id": "ADMET-03", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Name three common drivers of peptide immunogenicity (anti-drug antibody risk) and two mitigation strategies used in therapeutic peptide design.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 57082, "timestamp": "2026-02-09T10:45:06.939687+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-06", "question_id": "OPT-PEP-06", "pair_id": "OPT-06", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide binds both a target receptor and a homolog. Only the target has a unique Asp near the interface; the homolog has Asn at that position. What sequence modification strategy is most likely to improve selectivity, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 93932, "timestamp": "2026-02-09T10:51:36.703460+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-03", "question_id": "ASSAY-SM-03", "pair_id": "ASSAY-03", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound has IC50 = 50 nM on the intended target and IC50 = 5 µM on an off-target. Compute the selectivity ratio and interpret whether this is generally considered strong selectivity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Selectivity ratio:** **100-fold** (or 100×)\n\n**Calculation:**  \n5 µM = 5,000 nM  \nSelectivity = IC₅₀(off-target) / IC₅₀(on-target) = 5,000 nM / 50 nM = **100**\n\n**Interpretation:**  \nThis is generally considered **moderate to good selectivity**, meeting the minimum acceptable threshold (typically ≥100-fold) for many drug discovery programs. However, it is not exceptional:\n\n*   **<10-fold:** Poor (likely unacceptable)\n*   **10–100-fold:** Moderate (may be acceptable depending on the off-target risk)\n*   **>100-fold:** Good/selective\n*   **>1,000-fold:** Excellent/highly selective (often required for critical safety targets like hERG or major CYP isoforms)\n\nA 100-fold window provides a reasonable safety margin, though many programs aim for **≥1,000-fold** selectivity against high-risk off-targets to ensure robust therapeutic indices in vivo.", "latency_ms": 76679, "timestamp": "2026-02-09T10:52:56.383887+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-09", "question_id": "OPT-PEP-09", "pair_id": "OPT-09", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A baseline peptide has Kd = 1.0 µM. Mutation A gives Kd = 0.30 µM, mutation B gives Kd = 0.20 µM, and double mutant AB gives Kd = 0.020 µM. Under a multiplicative (log-additive) model, what Kd would you predict for AB, and does the result indicate synergy?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 25801, "timestamp": "2026-02-09T10:56:41.902142+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-03", "question_id": "OPT-SM-03", "pair_id": "OPT-03", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In a QSAR-guided lead-optimization loop, what minimum experimental data characteristics are needed to retrain reliably and reduce overfitting risk?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 43204, "timestamp": "2026-02-09T11:00:29.388533+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-05", "question_id": "ADMET-PEP-05", "pair_id": "ADMET-05", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A peptide’s renal filtration is approximately proportional to its free (unbound) fraction. If lipidation increases albumin binding and reduces fu from 0.5 to 0.01 (50-fold), what qualitative change do you expect in renal clearance and half-life (assume Vd is roughly unchanged)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Renal clearance** would decrease by approximately **50-fold** (proportional to the reduction in free fraction), and **half-life** would increase by approximately **50-fold**.\n\n**Rationale:**\n- Glomerular filtration is restricted to unbound drug, so renal clearance (CLᵣ", "latency_ms": 41347, "timestamp": "2026-02-09T11:01:13.736796+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-04", "question_id": "ADMET-PEP-04", "pair_id": "ADMET-04", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A therapeutic peptide has systemic clearance CL = 12 L/h and Vd = 4 L in humans. Estimate the terminal half-life and interpret what a Vd near 3–5 L typically implies about distribution.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Terminal half-life calculation:**\n\nUsing the relationship \\( t_{1/2} = \\frac{0.693 \\times V_d}{CL} \\):\n\n\\[ t_{1/2} = \\frac{0.693 \\times 4\\ \\text{L}}{12\\ \\text{L/h}} = \\frac{2.772}{12} \\approx \\mathbf{0.23\\ \\text{hours}}\\ (\\approx \\mathbf{14\\ \\text{minutes}}) \\]\n\n**Interpretation of Vd ≈ 3–5 L:**\n\nA volume of distribution in the 3–5 L range approximates the **plasma volume (~3 L) or total blood volume (~5 L)** in an average adult. This indicates:\n\n1. **Limited tissue distribution**: The peptide remains largely confined to the vascular (central) compartment with minimal penetration into peripheral tissues or cells\n2. **Hydrophilic character**: Consistent with peptides that cannot readily cross lipid membranes to access intracellular spaces or adipose tissue\n3. **Potential constraints**: May reflect high plasma protein binding, rapid renal filtration, or exclusion from the ~12 L of interstitial fluid due to size/charge\n\nFor context: Extracellular fluid Vd ≈ 15 L, total body water ≈ 40 L, while extensively distributed drugs can have Vd > 100 L.", "latency_ms": 60072, "timestamp": "2026-02-09T11:02:16.809417+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-05", "question_id": "ASSAY-SM-05", "pair_id": "ASSAY-05", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound’s apparent IC50 shifts from 1.0 µM with 5-minute preincubation to 50 nM with 60-minute preincubation. What mechanism does this suggest, and what follow-up assay distinguishes covalent from slow-tight binding?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The 20‑fold increase in potency (1.0 µM → 50 nM) with prolonged preincubation indicates **time‑dependent inhibition**, most consistent with either **slow‑tight binding** (slow onset, high‑affinity reversible binding) or **covalent/irreversible** inhibition.\n\n**Follow‑up assay to distinguish the two:**  \nA **jump‑dilution (reversibility) assay**:\n1. Preincubate the enzyme with the inhibitor (e.g., at 10 × IC₅₀) for 60 min to allow full binding.  \n2. Dilute the mixture 100‑fold into assay buffer containing saturating substrate.  \n3. Monitor enzymatic activity over time (e.g., 30–120 min).\n\n- **Covalent inhibitor:** No recovery of activity (remains >90 % inhibited) because dilution cannot reverse a chemical bond.  \n- **Slow‑tight binder:** Slow, exponential recovery of activity as the inhibitor dissociates (rate governed by *k*ₒff), typically reaching 50–100 % activity within minutes to hours depending on the residence time.\n\n**Alternative confirmation:** Mass spectrometry (detecting a mass shift corresponding to the inhibitor adduct) or dialysis/gel‑filtration followed by activity assay (irreversible inhibitors remain bound after buffer exchange; reversible inhibitors dissociate).", "latency_ms": 33091, "timestamp": "2026-02-09T11:02:52.900793+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-09", "question_id": "ASSAY-PEP-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Protease degradation of a peptide shows biphasic kinetics: 60% loss in the first 10 minutes, then slow decay over the next 2 hours. Give one kinetic explanation and one experiment that tests it.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 52410, "timestamp": "2026-02-09T11:07:26.831835+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-03", "question_id": "SAR-SM-03", "pair_id": "SAR-03", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand has a flexible linker (6 rotatable bonds) between two pharmacophoric groups. A co-crystal shows the bound conformation is U-shaped, but in solution the ligand is highly flexible. What is the most likely effect of macrocyclizing the linker to bias the U-shape, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The most likely effect is **increased binding affinity**, typically improving potency by **10- to 100-fold** (ΔΔG ≈ **1.4–2.8 kcal/mol** at 298 K), assuming the macrocycle does not introduce severe strain.\n\n**Reasoning:**\n\n1.  **Reduced Entropic Penalty:** The flexible linker", "latency_ms": 44433, "timestamp": "2026-02-09T11:09:57.140779+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-08", "question_id": "GEN-SM-08", "pair_id": "GEN-08", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You have a 3D pharmacophore with two H-bond acceptors ~7 Å apart and one hydrophobic feature. How can a generative model be conditioned to satisfy this, and what quantitative post-generation check verifies success?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Conditioning Strategies**\n\n1. **Pharmacophore-Distance Matrix Conditioning**  \n   Encode the 3D pharmacophore as a pairwise distance matrix (e.g., HBA₁–HBA₂ = 7 Å, HBA–hydrophobe = *d", "latency_ms": 52016, "timestamp": "2026-02-09T11:11:46.029295+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-08", "question_id": "OPT-PEP-08", "pair_id": "OPT-08", "category": "Optimization Approaches", "domain": "peptide", "question_text": "In designing an affinity-maturation library for a peptide, why do you typically limit the number of mutated positions per variant, and how does this relate to epistasis and library size?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In affinity maturation, you typically limit randomized positions to **2–4 residues per variant** (and rarely exceed 6) due to the constraints of **combinatorial explosion** and **epistatic interactions**.\n\n## Library Size Constraints\nThe theoretical diversity of a library randomizing *N* positions with 20 amino acids (e.g., NNK codons) is **20^N**. Practical display technologies have finite capacities:\n- **Phage", "latency_ms": 38898, "timestamp": "2026-02-09T11:12:27.928179+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-06", "question_id": "SAR-PEP-06", "pair_id": "SAR-06", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A stapled α-helical peptide binds a protein–protein interaction target, and CD measurements show ~60% helicity in solution. What is the most likely activity effect of removing the staple (keeping the same sequence otherwise), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Most likely effect:** A **10- to 100-fold decrease in binding affinity** (and corresponding cellular activity), with the unstapled peptide dropping to **<20%", "latency_ms": 39422, "timestamp": "2026-02-09T11:14:03.246874+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-05", "question_id": "OPT-PEP-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide lead clears rapidly primarily via renal filtration and proteolysis. Name two half-life extension strategies and explain which clearance component each mainly addresses.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 27665, "timestamp": "2026-02-09T11:18:12.161853+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-04", "question_id": "ASSAY-SM-04", "pair_id": "ASSAY-04", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A competitive inhibitor has IC50 = 100 nM in an assay run at substrate concentration [S] = 50 µM. The enzyme’s Km for substrate is 10 µM. Using Cheng–Prusoff, estimate Ki.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Using the Cheng–Prusoff equation for competitive inhibition:\n\n**Ki = IC50 / (1 + [S]/Km)**\n\nPlugging in the values:\n*   [S]/Km = 50 µM / 10 µM = **5**\n*   Ki = 100 nM / (1 + 5) = 100 nM / **6**\n\n**Ki ≈ 16.7 nM** (or approximately **17 nM**)\n\nThus, the true binding affinity of the inhibitor is roughly 6-fold tighter than the apparent IC50 measured under these assay conditions.", "latency_ms": 14403, "timestamp": "2026-02-09T11:18:29.565462+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-07", "question_id": "SAR-PEP-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds both a target protein and a close homolog. Only the target has a Tyr OH positioned to hydrogen-bond with a side-chain acceptor at the interface. What is the expected effect on potency and selectivity of substituting a Val at the interface to an Asn (introducing a side-chain carbonyl acceptor), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 61767, "timestamp": "2026-02-09T11:22:28.892656+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-09", "question_id": "SAR-PEP-09", "pair_id": "SAR-09", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s Lys side chain forms a salt bridge to an Asp on the target protein (N–O distance ~2.8 Å). You mutate Lys to Gln at that position. What is the most likely effect on binding/activity and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **", "latency_ms": 43381, "timestamp": "2026-02-09T11:23:15.274347+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-05", "question_id": "ADMET-SM-05", "pair_id": "ADMET-05", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A highly metabolized drug has high intrinsic clearance (CLint >> hepatic blood flow). Using the well-stirred model, how does decreasing the unbound fraction in plasma from fu = 0.01 to fu = 0.005 tend to change hepatic clearance, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 44165, "timestamp": "2026-02-09T11:26:56.474254+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-06", "question_id": "ADMET-PEP-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A 12-mer peptide has net charge +3 and many hydrogen-bond donors (backbone + side chains), giving poor cell permeability. Name two chemical strategies that can increase cell permeability while keeping the same amino-acid sequence identity largely intact, and explain why they work.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 33727, "timestamp": "2026-02-09T11:30:13.958302+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-08", "question_id": "ADMET-PEP-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Some cyclic peptides (~1000–1200 Da) can show measurable oral exposure despite violating Rule-of-Five guidelines. Name three molecular features that enable this and explain the mechanism in terms of effective polarity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 46804, "timestamp": "2026-02-09T11:34:36.215657+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-08", "question_id": "ASSAY-SM-08", "pair_id": "ASSAY-08", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound tested as a receptor agonist reaches only 60% of the maximal response produced by a known full agonist, even at saturating concentrations. What does this imply about the compound’s pharmacology, and how should EC50 be interpreted?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " This compound is a **partial agonist** with an **intrinsic efficacy** approximately 60% that of the full agonist (assuming the full agonist defines ε = 1.0).\n\n**Pharmacological Implications:**\n\n*   **Ceiling Effect:** The compound produces a submaximal response (60% Emax) even when 100% of receptors are occupied. It cannot elicit the full biological response regardless of concentration.\n*   **Functional Antagonism:** In the presence of a full agonist, this compound will competitively inhibit the full agonist's response while producing its own 60% effect. At high concentrations, it can reduce the full agonist's 100% response down to its own 60% ceiling (a net antagonism of 40%).\n*   **Spare Receptors:** Unlike full agonists, partial agonists generally cannot leverage spare receptors to achieve maximal tissue response.\n\n**EC50 Interpretation:**\n\nThe **EC50 remains a measure of potency (affinity)**, not efficacy. It is defined as the concentration producing **50% of the partial agonist's own maximal response** (i.e., the concentration yielding 30% of the full agonist's maximal effect).\n\n*   **Critical distinction:** EC50 does **not** indicate the concentration needed to reach 50% of the full agonist's response. It indicates the concentration needed to reach 30% of the full agonist's response (half of 60%).\n*   EC50 is independent of intrinsic efficacy; a partial agonist can have higher or lower affinity (lower or", "latency_ms": 46919, "timestamp": "2026-02-09T11:35:26.135911+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-02", "question_id": "SAR-PEP-02", "pair_id": "SAR-02", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s Asp side chain forms a salt bridge to a Lys on the target protein (distance ~2.8–3.0 Å) and is required for activity. What is the most likely effect on potency if Asp is substituted with Asn at that position, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Significant decrease in potency** (typically 10- to 100-fold or greater increase in IC₅₀/Kd).\n\n**Reasoning:**\nThe Asp→Asn substitution replaces a negatively charged carboxylate (–COO⁻) with a neutral carboxamide (–CONH₂). This eliminates the **salt bridge** (ionic interaction) with the target Lys (ε-NH₃⁺), which contributes approximately **3–5 kcal/mol** to binding affinity in a low-dielectric environment (e.g., a buried interface). \n\nWhile Asn can form hydrogen", "latency_ms": 34670, "timestamp": "2026-02-09T11:36:58.896108+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-08", "question_id": "SAR-SM-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A lead compound binds in a folded conformation. You add a gem-dimethyl group adjacent to the folding hinge (Thorpe–Ingold effect) to bias the folded conformation. If conformational preorganization improves binding free energy by ~1.0 kcal/mol, approximately what potency change (fold) would you expect at 298 K, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 33610, "timestamp": "2026-02-09T11:40:38.768074+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-01", "question_id": "ASSAY-PEP-01", "pair_id": "ASSAY-01", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Define MIC for an antimicrobial peptide and describe the typical dilution scheme used to measure it (include the standard concentration step size).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Minimum Inhibitory Concentration (MIC)** for an antimicrobial peptide (AMP) is defined as the lowest concentration of the peptide that inhibits visible growth of a specific microorganism (typically 10⁵–10⁶ CFU/mL) after a standardized incubation period (usually 16–24 hours at 35–37°C).\n\n**Typical Dilution Scheme:**\nThe standard method follows CLSI (M07) or ISO 20776-1 broth microdilution guidelines using 96-well microtiter plates:\n\n*   **Step size:** **2-fold (geometric) serial dilutions** (each concentration is 50% of the preceding one)\n*   **Concentration range:** Typically **128 µg/mL to 0.25 µg/mL** (or 0.5 µg/mL), though AMPs may require higher starting concentrations (up to 512 µg/mL) due to aggregation or reduced potency compared to conventional antibiotics\n*   **Format:** 100 µL peptide solution per well in cation-adjusted Mueller-Hinton broth (MHB), with final inoculum of ~5 × 10⁵ CFU/mL\n*   **Controls:** Growth control (no peptide), sterility control (no bacteria), and solvent control if peptides are dissolved in DMSO/acetic acid\n\n**AMP-Specific Considerations:** Due to AMPs' propensity for adsorption to polystyrene and aggregation at high concentrations, low-binding plates or supplemented media (e.g., 0.2% BSA or 0.01% Tween-20) are sometimes used to minimize surface binding, though these modifications must be reported as they can shift MIC values.", "latency_ms": 25640, "timestamp": "2026-02-09T11:41:07.408897+00:00", "success": true, "error": null}
